Evidence map›Paper›PMID 42831955›Full record

ArticleAdvances in therapy2026

Real-World Adherence Patterns and Predictors of GLP-1 Receptor Agonist Use for Obesity Management in a Medicaid Population.

Shadi Bazzazzadehgan, Eric Pittman, Liang-Yuan Lin, Junnan Qi, Amy Ly-Ha, Dennis Smith, Terri Kirby, Tyler A Vest, John P Bentley, Kaustuv Bhattacharya

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shadi BazzazzadehganDepartment of Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS, USA.
Eric PittmanDepartment of Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS, USA.
Liang-Yuan LinDepartment of Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS, USA.
Junnan QiDepartment of Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS, USA.
Amy Ly-HaMississippi Division of Medicaid, Jackson, MS, USA.
Dennis SmithMississippi Division of Medicaid, Jackson, MS, USA.
Terri KirbyMississippi Division of Medicaid, Jackson, MS, USA.
Tyler A VestResearch Institute for Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, USA.
John P BentleyDepartment of Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS, USA.
Kaustuv BhattacharyaDepartment of Pharmacy Administration, School of Pharmacy, University of Mississippi, University, MS, USA. kbhattac@olemiss.edu.ORCID http://orcid.org/0000-0001-8857-1817

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGlucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as effective anti-obesity medications (AOMs); however, real-world adherence and persistence patterns among Medicaid populations remain poorly understood, specifically after medication shortage resolution. This study examined adherence and persistence to GLP-1 RA AOMs among Mississippi (MS) Medicaid members following statewide coverage initiation in July 2023.

methodsThis cohort study utilized MS Medicaid claims data from January 2023 to December 2025. Members aged ≥ 18 years initiating GLP-1 RA AOMs between July 2023 and June 2025, with 6 months of continuous enrollment pre- and post-initiation, were included. Adherence rate was defined as percentage of members with proportion of days covered (PDC) greater than 0.8, and persistence rate was defined as percentage of members with continuous therapy without a 60-day gap, evaluated at 3- and 6-month intervals. Group-based trajectory modeling (GBTM) identified distinct adherence trajectories, and multinomial logistic regression assessed predictors of trajectory membership. A subgroup analysis was conducted for members initiating between July 2023 and December 2024, who had 12-month follow-up period.

resultsThe final analytic cohort included 3968 members, predominantly female (92.52%), Black (50.28%), and younger adults (18-39 years; 61.95%). Adherence rates declined from 56.85% at 3 months to 38.16% at 6 months, with persistence rates decreasing from 72.98% to 51.03% over the same period. In the 12-month subgroup analysis, adherence and persistence rates declined to 25.26% and 36.67%, respectively. GBTM identified five trajectories: consistent adherent (52.27%), delayed decliner (13.53%), consistent decliner (12.85%), fluctuating adherent (11.14%), and rapid discontinuer (10.21%). Treatment initiation in 2023, younger age, Black race, type 2 diabetes mellitus, and cardiovascular comorbidities were associated with suboptimal adherence trajectories, while managed care organization enrollment and hypertension were protective.

conclusionGLP-1 RA AOM adherence declines substantially over time among MS Medicaid members. Targeted interventions are needed to sustain long-term therapeutic engagement.

Indexed as

Adherence and persistenceAnti-obesity medicationsGlucagon-like peptide 1 receptor agonistsGroup-based trajectory modelingMedicaid

Identifiers

PMID42831955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.